Research Analysts Set Expectations for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of REGENXBIO in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will post earnings per share of $0.65 for the quarter. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q3 2025 earnings at $2.03 EPS and Q4 2025 earnings at ($1.44) EPS.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.

Several other analysts also recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research report on Tuesday, March 18th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Finally, The Goldman Sachs Group lowered REGENXBIO from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.88.

REGENXBIO Trading Down 6.0 %

Shares of RGNX stock opened at $6.16 on Thursday. REGENXBIO has a twelve month low of $5.04 and a twelve month high of $17.99. The stock has a fifty day simple moving average of $6.88 and a two-hundred day simple moving average of $8.22. The stock has a market capitalization of $308.72 million, a price-to-earnings ratio of -1.22 and a beta of 1.26.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently bought and sold shares of RGNX. Wealth Enhancement Advisory Services LLC purchased a new position in REGENXBIO in the first quarter worth $123,000. Pallas Capital Advisors LLC purchased a new position in REGENXBIO during the 1st quarter worth $74,000. GAMMA Investing LLC grew its stake in REGENXBIO by 372.1% during the 1st quarter. GAMMA Investing LLC now owns 16,188 shares of the biotechnology company’s stock worth $116,000 after buying an additional 12,759 shares during the last quarter. Alpine Global Management LLC acquired a new position in REGENXBIO during the 4th quarter valued at about $175,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in REGENXBIO by 9.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 6,105 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.